TLDR: Ryght AI, a leader in generative AI healthcare technology, has announced that the West Virginia University (WVU) Cancer Institute has joined its global site research network. This partnership aims to leverage Ryght’s advanced AI platform, featuring digital twins of research sites, to streamline clinical trial processes, enhance site selection, and ultimately improve patient access to innovative therapies, particularly in cancer research.
MORGANTOWN, WV – Ryght AI, a pioneering force in real-time generative artificial intelligence for healthcare and clinical research, today announced a significant expansion of its global site research network with the inclusion of the West Virginia University (WVU) Cancer Institute. This strategic collaboration, effective August 6, 2025, is set to revolutionize clinical trial processes by integrating cutting-edge AI solutions into the institute’s operations.
Ryght AI’s distinctive network is built upon the innovative concept of an AI digital twin for every research site worldwide. This advanced platform, powered by generative and agentic AI, is designed to significantly accelerate clinical trial study startup through faster site selection and streamlined feasibility workflows. By joining this network, the WVU Cancer Institute will gain access to state-of-the-art AI technologies, tools, and resources, fostering opportunities for collaboration with other leading institutions committed to advancing clinical research through AI.
Dr. Hannah Hazard-Jenkins, Executive Chair and Director of the WVU Cancer Institute and Professor of Surgery, expressed enthusiasm for the partnership. “We are excited to join the Ryght Research Network and to bring AI solutions to our physicians, researchers, trialists, and patients,” stated Dr. Hazard-Jenkins. “As an institution, we have always been committed to assuring our patients get access to innovative studies and life-saving therapies. Through this partnership with Ryght AI, we are destined to exactly achieve that.”
The collaboration aligns with Ryght AI’s core mission to bring evolving AI technologies to improve clinical trials’ access for every patient, with a shared goal of improving outcomes for all patients impacted by cancer. The Ryght Research Network leverages advanced generative AI capabilities to process both site-specific and industry-wide data, providing real-time insights that enable sponsors and Contract Research Organizations (CROs) to identify, select, and activate the most suitable sites for their trials. This also empowers sites like WVU to make data-driven decisions for running optimal studies for their patients.
For the WVU Cancer Institute, the partnership will foster interdisciplinary research and innovation, allowing researchers to explore new frontiers in AI and develop clinical trial solutions that rapidly expand access to patients across the state. The Morgantown-based institute is unique in West Virginia, being the only facility to offer patients specialized procedures such as blood and bone marrow transplants and and CAR-T cell therapy.
Also Read:
- AI and Ethics: Reshaping Healthcare and Clinical Trials for a New Era
- Revolutionizing Gait Analysis: Generative AI and Musculoskeletal Simulation Create Robust Clinical Models
Ryght AI has been actively expanding its research network, having previously added global CRO QPS Holdings in January and the University of Southern California’s Keck School of Medicine in December, underscoring its commitment to transforming clinical research globally.
